Lexicon’s Sotagliflozin Succeeds In Heart Failure Following Disappointment In Diabetes

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

Lexicon gets broad indication across heart failure for its dual SGLT1/2 inhibitor, which will be positioned against Lilly/BI’s Jardiance and AstraZeneca’s Farxiga.

Approval
Lexicon gets sotagliflozin approval in heart failure after missing in diabetes • Source: Shutterstock

After being thwarted in trying to bring its dual SGLT1/2 inhibitor sotagliflozin to market for type 1 diabetes, Lexicon Pharmaceuticals, Inc. got a big win with the drug with US Food and Drug Administration approval for heart failure with a broad label across the spectrum of heart failure, including decompensated patients who have been recently stabilized, which will be a unique claim versus the other SGLT inhibitors.

Lexicon said the drug, to be branded Inpefa, should be available in June and will priced in line with the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

Scrip-NewProducts (Premium-2): Top 12 Pharma Companies: Pfizer Tops The Leaderboard Again

 
• By Nabil

The world’s biggest pharmaceutical companies mostly saw growth in 2024 but 2025 promises to be more of a mixed bag with headwinds including losses of exclusivity, Medicare Part D redesign and challenges in the Chinese market.

Innovent/GenFleet Score China’s First KRAS G12C Inhibitor Approval

 
• By Dexter Jie Yan

The nod will help unlock a national market for the partners’ Dupert (fulzerasib) in which roughly 50,000 people are expected to be newly diagnosed with lung cancer harboring the KRAS G12C mutation in 2025. Meanwhile, two other homegrown rivals are also closing in on marketing clearances in China.

Cagrisema Leads The Charge For 2025

 
• By Elizabeth Cairns

2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.  

Small But Mitey: Tarsus To Amp Up Strong Xdemvy Launch

 
• By Alexandra Shimmings

Tarsus Pharmaceuticals is putting more sales and marketing heft behind its novel eyelid disease therapy, Xdemvy, to capitalize on a solid start in a previously untapped market.    

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda

Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains